What peptides do people stack with GLP-1s, and is it sensible?

The short answer

Because GLP-1s dominate the community, "what can I stack with my GLP-1?" is one of the most common stacking questions — and it has three recurring answers, each with a different level of sense behind it.

Evidence tier: The goals are real, but the gray-market stacks are mostly Tier 4. The amylin combination (CagriSema) is Tier 2 as a formulated drug; replicating it from research chemicals is not the same thing and carries Tier-4-level uncertainty.

The three things people add, and why:

• BPC-157 — to ease GI side effects (gut-healing rationale)
• Growth-hormone-axis peptides (CJC-1295/ipamorelin, tesamorelin) — to preserve muscle during rapid loss
• Amylin analogs (cagrilintide) — to push weight loss further

Some of these have a coherent rationale; none of the gray-market mix-it-yourself versions is proven as a combination. And the overriding point: GLP-1s are prescription drugs that already interact with other medications, so a clinician belongs in the loop. This is a companion to our stacking cornerstone.

Adding BPC-157 for GI side effects

Evidence tier: 4 — plausible rationale, no combination evidence.

The most common GLP-1 stack is BPC-157, usually added to settle the nausea, reflux, or general gut distress that comes with the early weeks. The rationale isn't crazy: BPC-157 has animal evidence for gut healing and mucosal protection, so the idea of using it to soothe a GI tract that the GLP-1 is irritating has surface logic.

But two cautions matter. First, there's no study of this combination — you're extrapolating from BPC-157's (thin, mostly animal) gut data to a use it was never tested for. Second, and more practically, most GLP-1 GI distress is a too-fast-titration problem, and the evidence-based fix is to slow the dose, not to add another compound. Reaching for BPC-157 to push through nausea you could resolve by titrating sensibly is solving the wrong problem. If you do add it, verify the BPC-157 source like any gray-market peptide and tell your prescriber. The titration-first approach is covered in our GLP-1 side effects guide and nausea management article.

Adding GH-axis peptides for muscle preservation

Evidence tier: 4 — real concern, unproven peptide solution.

Muscle loss during rapid weight loss is a legitimate worry — some of the weight lost on a GLP-1 is lean mass, not just fat. To counter it, people add growth-hormone-axis peptides like CJC-1295/ipamorelin or tesamorelin, reasoning that supporting growth hormone might protect muscle.

The problem isn't the goal; it's that the proven levers for muscle preservation are unglamorous and free: adequate protein intake and resistance training, which have real evidence behind them. Layering on gray-market GH-axis peptides is an unproven add-on, not a substitute for the basics, and many people who reach for the peptides haven't yet maximized the protein-and-lifting foundation that actually works. The honest sequence is to nail the fundamentals first; peptides are at most a speculative supplement to them, not a shortcut around them. We cover this in depth in our GLP-1 muscle preservation article.

Adding amylin (cagrilintide) for more weight loss

Evidence tier: 2 as a drug, 4 as a DIY stack — the distinction is the whole point.

This is the most interesting case because it's the one GLP-1 "stack" that's genuinely being developed as a medicine. CagriSema pairs cagrilintide — a long-acting amylin analog that promotes satiety through a separate pathway — with semaglutide, and trials showed it can push weight loss beyond semaglutide alone. So the concept of an amylin + GLP-1 combination has real, trial-level support.

But there's a crucial distinction: CagriSema is a single, formulated, dose-matched, trial-tested product. Buying separate research-chem cagrilintide and a GLP-1 and combining them yourself is not the same thing — you're improvising doses of an unverified amylin peptide alongside your GLP-1, without the formulation work or the safety data that made the actual drug trustworthy. The lesson generalizes: "a pharma company is developing this combination" is evidence for the concept, not a green light to replicate it from gray-market parts. See our next-gen multi-agonists overview for where these combinations are heading as actual drugs.

What's the overriding safety consideration?

Evidence tier: 2 — documented drug-interaction reality.

Above all the peptide-specific points sits one that applies to anything you add to a GLP-1: GLP-1s are prescription medications with real, documented interactions. Combined with insulin or sulfonylureas they raise hypoglycemia considerations; they affect gastric emptying, which can alter the absorption of other oral medications. Your prescriber needs to know about anything you're adding — peptide, supplement, or otherwise — because they hold the information about your other medications and conditions that makes the combination safe or not.

On top of that, GLP-1 stacks carry the general stacking risks from our stacking safety and interactions article: each gray-market peptide multiplies sourcing uncertainty, side effects can stack, and starting several things at once destroys your ability to tell what caused a problem. So the rule is doubly firm here: loop in your clinician, and add one thing at a time.

What about non-peptide additions people stack with GLP-1s?

Evidence tier: 2–4 — varies by addition; mostly supportive or unproven.

Not everything people add to a GLP-1 is a peptide, and the non-peptide additions deserve a quick honest sorting because the community discusses them constantly. The genuinely sensible additions are the unglamorous ones: adequate protein (to protect lean mass), fibre and fluids (to manage the constipation GLP-1s commonly cause), electrolytes (helpful if intake drops sharply), and resistance training (the real muscle-preservation tool). These aren't "stacks" so much as the supportive basics that make the drug work better and feel better, and they have real evidence behind them.

Then there's the large and mostly-unproven category of supplements marketed specifically to GLP-1 users — "GLP-1 support" blends, metabolism boosters, and the like. Most of these lack good evidence, add cost and complexity, and can themselves cause GI upset that muddies your read on the drug. They trade on the appeal of doing something extra, but the something that actually matters is protein, hydration, fibre, sleep, and movement. Be especially wary of anything promising to "enhance" or "potentiate" the GLP-1 — that framing is marketing, not pharmacology.

The one category that genuinely needs caution is anything that affects the same systems the GLP-1 does — blood-sugar-lowering supplements stacked on a drug that already lowers glucose, for instance, or stimulants on top of a drug that already raises heart rate. These can produce additive effects that aren't obvious until they're a problem, and they're exactly the kind of thing your prescriber should know about.

The throughline is the same as for peptide additions: most of what people stack onto a GLP-1 is either a sensible supportive basic (which you should do) or an unproven add-on (which mostly adds cost and noise). The drug plus the fundamentals — protein, fibre, hydration, training, sleep, sensible titration — is the protocol that the evidence actually supports. Everything beyond that should clear a real "why," and anything touching glucose, heart rate, or your prescription medications belongs in a conversation with your clinician rather than a forum thread.

Limitations

This is an educational and harm-reduction guide, not medical advice.

• GLP-1s are prescription drugs with documented interactions — your prescriber must know what you add.
• None of these gray-market stacks is proven as a combination — rationale is not proof.
• The evidence-based muscle-preservation tools are protein and resistance training, not peptides.
• CagriSema is a formulated drug, not a DIY template — replicating it from research chemicals is different and riskier.
• General stacking risks apply — sourcing, additive side effects, attribution.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

People stack three kinds of peptide with GLP-1s: BPC-157 for GI side effects, GH-axis peptides for muscle, and amylin analogs for more weight loss. The GI and muscle stacks have plausible goals but unproven gray-market execution — and both have better first-line answers (slower titration; protein and lifting). The amylin combination is real enough that it's becoming a drug, but a formulated, trial-tested drug is not the same as a self-mixed research-chem stack. Overriding all of it: GLP-1s interact with prescription medications, so whatever you add belongs in a conversation with your clinician, introduced one compound at a time.

A final reframing worth holding: the GLP-1 itself is already doing the heavy lifting, and the instinct to stack often comes from wanting to feel like you're optimizing rather than from a genuine gap the drug leaves. In most cases the highest-value "additions" aren't compounds at all — they're the behaviors that compound the drug's benefit and blunt its side effects. If you find yourself reaching for a third or fourth peptide to add to a GLP-1, it's worth asking whether you've first maximized protein, training, hydration, sleep, and a sensible titration, because those are where the real, evidence-backed gains sit. Stacking more compounds onto an already-powerful drug is usually adding risk and cost at the margin, not unlocking a hidden tier of results.

Related on this site

• Peptide stacking: what's safe, what works, what's hype
• Peptide stacking safety and interactions
• GLP-1 side effects and how to manage them
• GLP-1 nausea: how to manage it
• GLP-1 muscle preservation
• Next-gen multi-agonists overview
• GLP-1 complete guide (2026)
• Our evidence-tier framework
• Finnrick vendor testing

References

• Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 387(3):205-216. PMID 35658024 — GLP-1/GIP efficacy and adverse-effect baseline.
• Enebo LB, Berthelsen KK, Kankam M, et al. 2021. Safety and efficacy of cagrilintide plus semaglutide in obesity: a randomised phase 1b trial. Lancet. 397(10286):1736-1748. PMID 33894838 — amylin + GLP-1 combination as a formulated drug.
• Sikiric P, Seiwerth S, Rucman R, et al. 2013. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 19(1):126-132. PMID 23330536 — BPC-157 gut evidence (basis for the GI-stack rationale).
• U.S. Food and Drug Administration. Ozempic / Wegovy (semaglutide) prescribing information. FDA.gov — labeled drug interactions and hypoglycemia considerations.